Health Care · Laboratory Analytical Instruments · Nasdaq · CIK 1770787 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $46.32Day −1.55%Mkt cap $5.8B1Y +230.9%Off 52W high −6.4%Vol (1Y) 69.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,723 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest13.0% of sh out |
| Days to cover5.3d |
| 13F net flow (QoQ)+0.98% |
| Top-10 13F concentration59.3% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$638.8M |
| Earnings (TTM)-$22.7M |
| ROE−5.8% |
| Net margin−6.8% |
| Sales growth 3Y7.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+184.0% |
| 1Y+230.9% |
| 3Y−26.5% |
| 5Y−74.8% |
| Since incept. (ann.)−1.9% |
Total return through 2026-07-29 · series begins 2019-09-12. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)69.7% |
| Ann. volatility (3Y)67.1% |
| Sharpe (1Y)2.03 |
| Sharpe (3Y)0.18 |
| Max drawdown (1Y)−28.0% |
| Max drawdown (3Y)−88.7% |
| Beta (3Y vs SPY)1.89 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 17.7M | $377M | 14.22% | +48.9% |
| ARK Investment Management LLC | 11.7M | $249M | 9.39% | −7.5% |
| BlackRock, Inc. | 10.1M | $214M | 8.08% | +0.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.9M | $147M | 5.54% | new |
| Quantinno Capital Management LP | 5.4M | $115M | 4.34% | +16.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.3M | $112M | 4.22% | new |
| Sumitomo Mitsui Trust Group, Inc. | 5.1M | $108M | 4.10% | −7.0% |
| Amova Asset Management Americas, Inc. | 5.1M | $108M | 4.09% | −7.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 100.3% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 16,248,294 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.10 | — | $150.8M | −2.6% |
| 2025-12-31 | 2026-02-12 | — | — | $166.0M | +0.6% |
| 2025-09-30 | 2025-11-06 | −$0.22 | — | $149.0M | −1.7% |
| 2025-06-30 | 2025-08-07 | $0.28 | — | $172.9M | +12.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Americas 32% · US 31% · EMEA 14% · Asia Pacific 11% · CN 6%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
